The clinical trial matching app, which Roche collaborated on with MolecularMatch, is the latest in a series of features that it will introduce in its tumor board solution.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
